We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 27, 2020

Dasatinib Plus Decitabine in Accelerated or Blast Phase CML

American Journal of Hematology


Additional Info

Disclosure statements are available on the authors' profiles:

American Journal of Hematology
Phase I/II Study of Dasatinib in Combination With Decitabine in Patients With Accelerated or Blast Phase Chronic Myeloid Leukemia
Am. J. Hematol 2020 Jul 18;[EPub Ahead of Print], Y Abaza, H Kantarjian, Y Alwash, G Borthakur, R Champlin, T Kadia, G Garcia-Manero, N Daver, F Ravandi, S Verstovsek, J Burger, Z Estrov, M Ohanian, M Lim, N Pemmaraju, E Jabbour, J Cortes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading